Table 2.
Peak expiratory flow (PEF) & forced expiratory volume in 1 second (FEV1) in patients receiving montelukast vs. placebo
|
Montelukast |
Placebo |
p value | |||
|---|---|---|---|---|---|
| n | Mean (±SD) | n | Mean (±SD) | ||
| PEF at admission |
50 |
123.82 (±48.76) |
50 |
144.70 (±78.85) |
0.11 |
| PEF at day 2 |
50 |
149.48 ± 75.76 |
50 |
173.41 ± 103 |
0.20 |
| PEF at day3 |
50 |
164.50 ±82.74 |
50 |
183.35 ± 113.12 |
0.47 |
| PEF at discharge |
50 |
160.12 (±77.00) |
50 |
187.08 (±108.93) |
0.15 |
| FEV1 at admission |
50 |
0.82 (±0.35) |
50 |
0.90 (±0.60) |
0.46 |
| FEV1 at discharge | 50 | 1.07 (±0.54) | 50 | 1.21 (±0.68) | 0.29 |